Quarterly report [Sections 13 or 15(d)]

Segment Reporting

v3.26.3
Segment Reporting
9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting

Note 9 – Segment Reporting

 

We manage our operations as a single segment, focused on advancing the clinical-stage BTKi program and evaluating our legacy pharmaceutical assets. As our chief operating decision maker, our CEO manages and allocates resources at a consolidated level. He assesses performance, monitors budget versus actual results, and decides how to allocate resources based on net loss that also is reported on the consolidated statement of operations and comprehensive loss as consolidated net loss.

 

The following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable segment for the three and nine months ended September 30, 2026 and 2025 (in thousands):

 

    2026     2025     2026     2025  
    Three Months Ended September 30,     Nine Months Ended September 30,  
    2026     2025     2026     2025  
Preclinical, clinical trial and other costs   $ 1,465     $ 1,204     $ 3,214     $ 4,543  
Research and development personnel expense(1)     346       458       1,056       1,154  
Acquired IPR&D expense    

178,030

     

-

     

178,030

     

-

 
General and administrative personnel expense(2)     705       855       1,967       2,158  
Administrative and facilities expense(3)     3,583       972       5,530       2,432  
Other expense, net(4)     (972 )     (52 )     3       (82 )
Total   $ 183,157     $ 3,437     $ 189,800     $ 10,205  

 

(1)   Research and development personnel costs include employee stock-based compensation expense of $57 and $110 for the three months ended September 30, 2026 and 2025, respectively, and $92 and $166 for the nine months ended September 30, 2026 and 2025, respectively.
(2)   General and administrative personnel costs include employee stock-based compensation expense of $182 and $193 for the three months ended September 30, 2026 and 2025, respectively, and $283 and $438 for the nine months ended September 30, 2026 and 2025, respectively, and are net of reimbursements received from CorLyst, LLC.
(3)   Administrative & facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and other administrative costs.
(4)   Other income, net consists of interest and dividend income, realized and unrealized losses on our digital assets, and other miscellaneous income.